摘要
磺脲类、格列奈类和噻唑烷二酮类药物(thiazolidinediones,TZDs)长期使用均可使患者体重不同程度增加。磺脲类药物在临床应用时间长,经济且疗效确切,在糖尿病的治疗中占有重要的地位,其主要不良反应为体重增加和低血糖。与磺脲类药物相比较,格列奈类药物具有起效快、作用时间短的特点,其主要作用是改善早相胰岛素分泌从而控制餐后血糖,低血糖发生率低,总体安全性较好。TZDs被认为是经典的胰岛素增敏剂,降糖效果肯定,且单独使用时不导致低血糖。TZDs长期使用会增加骨折的发生,但目前没有证据表明会增加心血管事件和膀胱癌的发生率。
Long-term sulfonylureas, glinides and thiazolidinediones treatment can increase the body weight of the patients with diabetes. Sulfonylureas have long history in the clinical application with the economy and the curative effect, which pay an important role in the treatment of diabetes. The main adverse reactions of sulfonylureas is hypoglycemia. Compared to sulfonylureas, glinides are agents by stimulating early-phase insulin secretion to control postprandial blood glucose, whose action occurs rapidly and sustains shortly. Generally apeaking, the safety of glinides is good because of low incidence rate of hypoglycemia. TZDs are known as classical insulin sensitizers with effective hypoglycemic role. No sufficient evidence show that TZDs increase the risk of bladder cancer and cardiovascular events.
出处
《药品评价》
CAS
2018年第3期34-37,59,共5页
Drug Evaluation
